NASDAQ · STOCK
Vertex Pharmaceuticals
$477.02
52W $362.50 – $533.67
57/100
$121.09B
28.0
0.29
Is VRTX Bullish or Bearish?
Mixed.
Innellis AI committee rates Vertex Pharmaceuticals (VRTX) Watch with a composite score of 57/100
, based on 7 analysts with 86% agreement.
Last updated July 31, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +3.26 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -16.74 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
Some positive signals exist — low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull & Bear Case
Bull Case
- ROE of 23.9% shows genuine earnings power backing the valuation — Value
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock — Risk
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- P/E of 27.8 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of July 31, 2026
Overall Committee Score
57/100
Agreement
86%
Analysts
7
Conviction
High
Sector Rank
Top 40%
of 93 Healthcare peers
Value Analyst
neutral
54
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 23.9% shows genuine earnings power backing the valuation
− P/E of 27.8 is moderate-to-rich
Growth Analyst
neutral
50
/ 100 · Moderate confidence
Moderate growth -- present but not remarkable
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
neutral
51
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock
Macro Analyst
neutral
58
/ 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
neutral
60
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Investment Thesis Evolution
Committee score moved marginally from 57.5 to 56.7.
- Conviction changed from moderate to high.
- Committee agreement increased notably from 71% to 86%.
- New bearish signals: 3 appeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 3 signal(s) disappeared.
- Analyst(s) changed stance: Macro Analyst.
Analyst-level changes:
- Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
- Portfolio Manager: +2 bearish signal(s).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-07-30 to 2026-07-31 (1 day apart).
Technical Analysis
RSI (14)
42.8
Neutral
MACD Histogram
-1.863
Bearish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Hh Hl
Support
$458.47
Resistance
$483.18
Bollinger %B
0.34
Inside Bands
Price vs Moving Averages
EMA 9
$481.16
Below
EMA 21
$481.36
Below
EMA 50
$472.51
Above
EMA 200
$455.95
Above
Fundamental Analysis
Valuation
58
Growth
37
Profitability
1
Financial Health
100
Cash Flow
37
Valuation
P/E Ratio
28.0×
P/B Ratio
6.26×
PEG Ratio
0.05
Dividend Yield
0.00%
52W High
$533.67
52W Low
$362.50
Quality & Growth
ROE
21.2%
ROA
15.1%
Gross Margin
86.3%
Operating Margin
39.0%
Revenue Growth YoY
—
Debt / Equity
0.10
AI Fundamental Assessment
P/E ratio of 28.0 (moderate relative to a 15-40x range); Price-to-book of 6.3x; PEG ratio of 0.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.2%; Return on assets of 0.2%; Net margin of 0.4%; Gross margin of 0.9%; Current ratio of 3.02 (healthy short-term liquidity); Debt-to-equity of 0.10; Free cash flow margin of 0.9% (thin cash generation); Free cash flow per share is positive (14.60); Most recent quarter beat estimates by 1.7%; EPS growth decelerating (+4.8% -> -11.1% QoQ); Analyst estimates falling over recent quarters
Get the Full VRTX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →